TTrialPathMatch Me to Trials
← Back to trials
RecruitingMajor Depressive Disorder

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

Eligible age

18–65 yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder

Sponsor: Bristol-Myers Squibb

You may qualify if…

  • ✓ Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview.
  • ✓ Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.
  • ✓ Participant must have current MDE duration \>12 weeks at screening.
  • ✓ Outpatient participants able to comply with study procedures.
  • ✓ Participant require medication washout completed before baseline.
  • ✓ Participant must have BMI within protocol range.
  • ✓ Participants must meet reproductive safety requirements.

You may not qualify if…

  • ✕ Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.
  • ✕ Participants must not have recent history of active suicidal ideation or attempt within the past year.
  • ✕ Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation.
  • ✕ Participants must not have recent history of alcohol/substance abuse or use of cannabis.
  • ✕ Participants must not have significant ECG abnormalities, or poorly controlled diabetes.
  • ✕ Other protocol defined inclusion/exclusion criteria apply.

Where it's recruiting

Arizona

Phoenix

Arkansas

Little Rock · Rogers

California

Garden Grove · Glendale · Lemon Grove · Oakland …

Florida

Jacksonville · Orlando

Georgia

Atlanta

Maryland

Gaithersburg

New York

Cedarhurst · Mount Kisco · Staten Island

Ohio

Columbus

Oklahoma

Oklahoma City

Washington

Everett

Source: ClinicalTrials.gov · NCT07772531 · last updated 2026-11-18